<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445705</url>
  </required_header>
  <id_info>
    <org_study_id>203818-503</org_study_id>
    <nct_id>NCT00445705</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <brief_summary>
    <textblock>
      This study will explore the safety and effectiveness of different doses of AGN 203818 in
      treating the pain associated with fibromyalgia syndrome. The study is being conducted in 2
      parts. Part A enrolled 211 pts dosed with either 3, 20, 60 mg BID AGN 203818 or placebo over
      4 week treatment duration. Part B will enroll 440 pts and dose with either 20, 100, 160 mg
      BID AGN 203818 or placebo over 12 week treatment duration.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was terminated early due to company decision. Part B was never conducted.
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Daily-Average-Pain Score at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Change from Baseline in mean daily-average-pain score at week 4. Patients recorded their daily average pain on a 11-point scale (where 0 equals no pain and 10 equals worst pain imaginable) using a diary during the 4-week treatment period. A negative number change from baseline represents a decrease in average pain (improvement).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Short Form Brief Pain Inventory (SF-BPI) Average Pain Score at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Change from baseline in the SF-BPI average pain question score at week 4. The SF-BPI is a patient-rated questionnaire that assesses certain aspects of pain including location, intensity, and interference with certain daily activities. The &quot;average pain&quot; question was rated on an 11-point scale (where 0=no pain and 10=worst pain imaginable). A negative number change from baseline indicates a reduction in average pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Fibromyalgia Impact Questionnaire (FIQ) Total Score of Physical Impairment at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Change from baseline in FIQ total score of physical impairment at week 4. The FIQ is a disease-specific questionnaire consisting of 10 questions and visual analog scales regarding functional disability, pain intensity, sleep function, stiffness, anxiety, depression, and overall sense of wellbeing. Each question is scored from 0 to 10 with 0 = no impairment (best) and 10 indicates maximum impairment (worst), for a minimum possible score (best) of 0 and a maximum possible (worst) total score of 100. A negative number change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) for Fibromyalgia Syndrome Status at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>PGIC status for fibromyalgia syndrome at week 4. The PGIC consists of a self-evaluation by the patient of the overall change of their fibromyalgia syndrome since the beginning of the study, rated on a 7-point scale (score of 1-3 = very much improved to minimally improved; 4= no change; 5-7 = minimally worse to very much worse). Results are presented for the percentage of patients reporting each status: &quot;improved&quot;= score of 1-3; &quot;no change&quot;=score of 4; and &quot;worse&quot;=score of 5-7.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A: Placebo every 12 hours for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN 203818 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: 3 mg AGN 203818 every 12 hours for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN 203818 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: 20 mg AGN 203818 every 12 hours for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN 203818 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: 60 mg AGN 203818 every 12 hours for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Part A: Placebo every 12 hours for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN 203818</intervention_name>
    <description>Part A: AGN 203818 3 mg every 12 hours for 4 weeks</description>
    <arm_group_label>AGN 203818 3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN 203818</intervention_name>
    <description>Part A: AGN 203818 20 mg every 12 hours for 4 weeks</description>
    <arm_group_label>AGN 203818 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN 203818</intervention_name>
    <description>Part A: AGN 203818 60 mg every 12 hours for 4 weeks</description>
    <arm_group_label>AGN 203818 60 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of fibromyalgia syndrome

          -  Moderate or severe pain associated with fibromyalgia

        Exclusion Criteria:

          -  Any other uncontrolled disease

          -  Pregnant or nursing females
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanmore</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <results_first_submitted>December 16, 2011</results_first_submitted>
  <results_first_submitted_qc>December 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2012</results_first_posted>
  <last_update_submitted>August 25, 2015</last_update_submitted>
  <last_update_submitted_qc>August 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Part A: Placebo every 12 hours for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>AGN 203818 3 mg</title>
          <description>Part A: 3 mg AGN 203818 every 12 hours for 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>AGN 203818 20 mg</title>
          <description>Part A: 20 mg AGN 203818 every 12 hours for 4 weeks</description>
        </group>
        <group group_id="P4">
          <title>AGN 203818 60 mg</title>
          <description>Part A: 60 mg AGN 203818 every 12 hours for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Part A: Placebo every 12 hours for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>AGN 203818 3 mg</title>
          <description>Part A: 3 mg AGN 203818 every 12 hours for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>AGN 203818 20 mg</title>
          <description>Part A: 20 mg AGN 203818 every 12 hours for 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>AGN 203818 60 mg</title>
          <description>Part A: 60 mg AGN 203818 every 12 hours for 4 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="53"/>
            <count group_id="B5" value="211"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" lower_limit="23" upper_limit="68"/>
                    <measurement group_id="B2" value="50.0" lower_limit="25" upper_limit="69"/>
                    <measurement group_id="B3" value="49.5" lower_limit="18" upper_limit="67"/>
                    <measurement group_id="B4" value="51.0" lower_limit="24" upper_limit="71"/>
                    <measurement group_id="B5" value="50.0" lower_limit="18" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Daily-Average-Pain Score at Week 4</title>
        <description>Change from Baseline in mean daily-average-pain score at week 4. Patients recorded their daily average pain on a 11-point scale (where 0 equals no pain and 10 equals worst pain imaginable) using a diary during the 4-week treatment period. A negative number change from baseline represents a decrease in average pain (improvement).</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Modified Intent-To-Treat (m-ITT). The m-ITT population included all patients who started the study (randomized) and received study medication with at least one post-treatment mean daily-average-pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part A: Placebo every 12 hours for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>AGN 203818 3 mg</title>
            <description>Part A: 3 mg AGN 203818 every 12 hours for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>AGN 203818 20 mg</title>
            <description>Part A: 20 mg AGN 203818 every 12 hours for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>AGN 203818 60 mg</title>
            <description>Part A: 60 mg AGN 203818 every 12 hours for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Daily-Average-Pain Score at Week 4</title>
          <description>Change from Baseline in mean daily-average-pain score at week 4. Patients recorded their daily average pain on a 11-point scale (where 0 equals no pain and 10 equals worst pain imaginable) using a diary during the 4-week treatment period. A negative number change from baseline represents a decrease in average pain (improvement).</description>
          <population>Modified Intent-To-Treat (m-ITT). The m-ITT population included all patients who started the study (randomized) and received study medication with at least one post-treatment mean daily-average-pain score.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="1.04"/>
                    <measurement group_id="O2" value="6.7" spread="1.10"/>
                    <measurement group_id="O3" value="6.6" spread="0.96"/>
                    <measurement group_id="O4" value="6.7" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.66"/>
                    <measurement group_id="O2" value="-1.2" spread="1.82"/>
                    <measurement group_id="O3" value="-1.5" spread="1.79"/>
                    <measurement group_id="O4" value="-1.5" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Short Form Brief Pain Inventory (SF-BPI) Average Pain Score at Week 4</title>
        <description>Change from baseline in the SF-BPI average pain question score at week 4. The SF-BPI is a patient-rated questionnaire that assesses certain aspects of pain including location, intensity, and interference with certain daily activities. The “average pain” question was rated on an 11-point scale (where 0=no pain and 10=worst pain imaginable). A negative number change from baseline indicates a reduction in average pain.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Modified Intent-To-Treat (m-ITT). The m-ITT population included all patients who started the study (randomized) and received study medication with at least one post-treatment mean daily-average-pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part A: Placebo every 12 hours for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>AGN 203818 3 mg</title>
            <description>Part A: 3 mg AGN 203818 every 12 hours for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>AGN 203818 20 mg</title>
            <description>Part A: 20 mg AGN 203818 every 12 hours for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>AGN 203818 60 mg</title>
            <description>Part A: 60 mg AGN 203818 every 12 hours for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Short Form Brief Pain Inventory (SF-BPI) Average Pain Score at Week 4</title>
          <description>Change from baseline in the SF-BPI average pain question score at week 4. The SF-BPI is a patient-rated questionnaire that assesses certain aspects of pain including location, intensity, and interference with certain daily activities. The “average pain” question was rated on an 11-point scale (where 0=no pain and 10=worst pain imaginable). A negative number change from baseline indicates a reduction in average pain.</description>
          <population>Modified Intent-To-Treat (m-ITT). The m-ITT population included all patients who started the study (randomized) and received study medication with at least one post-treatment mean daily-average-pain score.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="1.19"/>
                    <measurement group_id="O2" value="6.6" spread="1.21"/>
                    <measurement group_id="O3" value="6.5" spread="1.23"/>
                    <measurement group_id="O4" value="6.5" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.88"/>
                    <measurement group_id="O2" value="-1.2" spread="1.79"/>
                    <measurement group_id="O3" value="-1.7" spread="2.24"/>
                    <measurement group_id="O4" value="-1.3" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Fibromyalgia Impact Questionnaire (FIQ) Total Score of Physical Impairment at Week 4</title>
        <description>Change from baseline in FIQ total score of physical impairment at week 4. The FIQ is a disease-specific questionnaire consisting of 10 questions and visual analog scales regarding functional disability, pain intensity, sleep function, stiffness, anxiety, depression, and overall sense of wellbeing. Each question is scored from 0 to 10 with 0 = no impairment (best) and 10 indicates maximum impairment (worst), for a minimum possible score (best) of 0 and a maximum possible (worst) total score of 100. A negative number change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Modified Intent-To-Treat (m-ITT). The m-ITT population included all patients who started the study (randomized) and received study medication with at least one post-treatment mean daily-average-pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part A: Placebo every 12 hours for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>AGN 203818 3 mg</title>
            <description>Part A: 3 mg AGN 203818 every 12 hours for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>AGN 203818 20 mg</title>
            <description>Part A: 20 mg AGN 203818 every 12 hours for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>AGN 203818 60 mg</title>
            <description>Part A: 60 mg AGN 203818 every 12 hours for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Fibromyalgia Impact Questionnaire (FIQ) Total Score of Physical Impairment at Week 4</title>
          <description>Change from baseline in FIQ total score of physical impairment at week 4. The FIQ is a disease-specific questionnaire consisting of 10 questions and visual analog scales regarding functional disability, pain intensity, sleep function, stiffness, anxiety, depression, and overall sense of wellbeing. Each question is scored from 0 to 10 with 0 = no impairment (best) and 10 indicates maximum impairment (worst), for a minimum possible score (best) of 0 and a maximum possible (worst) total score of 100. A negative number change from baseline indicates improvement.</description>
          <population>Modified Intent-To-Treat (m-ITT). The m-ITT population included all patients who started the study (randomized) and received study medication with at least one post-treatment mean daily-average-pain score.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9" spread="15.35"/>
                    <measurement group_id="O2" value="65.5" spread="15.55"/>
                    <measurement group_id="O3" value="65.7" spread="13.63"/>
                    <measurement group_id="O4" value="63.0" spread="13.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="16.67"/>
                    <measurement group_id="O2" value="-15.1" spread="18.17"/>
                    <measurement group_id="O3" value="-18.7" spread="20.51"/>
                    <measurement group_id="O4" value="-12.8" spread="20.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Change (PGIC) for Fibromyalgia Syndrome Status at Week 4</title>
        <description>PGIC status for fibromyalgia syndrome at week 4. The PGIC consists of a self-evaluation by the patient of the overall change of their fibromyalgia syndrome since the beginning of the study, rated on a 7-point scale (score of 1-3 = very much improved to minimally improved; 4= no change; 5-7 = minimally worse to very much worse). Results are presented for the percentage of patients reporting each status: “improved”= score of 1-3; “no change”=score of 4; and “worse”=score of 5-7.</description>
        <time_frame>Week 4</time_frame>
        <population>Modified Intent-To-Treat (m-ITT). The m-ITT population included all randomized patients who started study (randomized) and who received the study medication with at least one post-treatment mean daily-average-pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part A: Placebo every 12 hours for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>AGN 203818 3 mg</title>
            <description>Part A: 3 mg AGN 203818 every 12 hours for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>AGN 203818 20 mg</title>
            <description>Part A: 20 mg AGN 203818 every 12 hours for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>AGN 203818 60 mg</title>
            <description>Part A: 60 mg AGN 203818 every 12 hours for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Change (PGIC) for Fibromyalgia Syndrome Status at Week 4</title>
          <description>PGIC status for fibromyalgia syndrome at week 4. The PGIC consists of a self-evaluation by the patient of the overall change of their fibromyalgia syndrome since the beginning of the study, rated on a 7-point scale (score of 1-3 = very much improved to minimally improved; 4= no change; 5-7 = minimally worse to very much worse). Results are presented for the percentage of patients reporting each status: “improved”= score of 1-3; “no change”=score of 4; and “worse”=score of 5-7.</description>
          <population>Modified Intent-To-Treat (m-ITT). The m-ITT population included all randomized patients who started study (randomized) and who received the study medication with at least one post-treatment mean daily-average-pain score.</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8"/>
                    <measurement group_id="O2" value="67.4"/>
                    <measurement group_id="O3" value="69.1"/>
                    <measurement group_id="O4" value="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="21.7"/>
                    <measurement group_id="O3" value="23.8"/>
                    <measurement group_id="O4" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="10.9"/>
                    <measurement group_id="O3" value="7.1"/>
                    <measurement group_id="O4" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety population was used to calculate the number of participants at risk for SAEs and AEs and is the total number of patients that were randomized AND treated.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Part A: Placebo every 12 hours for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>AGN 203818 3 mg</title>
          <description>Part A: 3 mg AGN 203818 every 12 hours for 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>AGN 203818 20 mg</title>
          <description>Part A: 20 mg AGN 203818 every 12 hours for 4 weeks</description>
        </group>
        <group group_id="E4">
          <title>AGN 203818 60 mg</title>
          <description>Part A: 60 mg AGN 203818 every 12 hours for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early due to company decision. Only Part A results are presented; Part B was never conducted.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

